During the company’s most recent earnings call, LabCorp CEO David King said the company was preparing to launch the wellness testing offering. As he explained at the time, the offering will be expanded and will have application in its drug development business, Covance.
The offering falls in line with the company’s aim to support trials with “convenient, accurate testing outside the physician office,” King said.
“The ability to make testing more accessible and convenient can help support clinical research in a variety of ways, from initial eligibility screening to remote patient monitoring,” Donald Von Hagen, LabCorp, vice president, corporate communications, told us.
“We plan to pursue these types of opportunities in the future as we continue to develop Pixel by LabCorp,” he said.
The test packages can be purchased at Pixel.LabCorp.com and include a physician review and order, which are required for all Pixel by LabCorp testing, the company explained. Most testing requires a few drops of blood collected from the fingertip.
The offering will initially provide screens for wellness, heart health, diabetes, and colorectal cancer.
